We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+8.94%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$76.2B
AUM Growth
+$2.6B
(+3.5%)
Cap. Flow
-$2.97B
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
21.61%
Holding
3,238
New
235
Increased
684
Reduced
2,065
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$77.3M |
| 2 |
Blackstone
BX
|
+$53.2M |
| 3 |
NXP Semiconductors
NXPI
|
+$40.8M |
| 4 |
Palantir
PLTR
|
+$34.3M |
| 5 |
Snowflake
SNOW
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$206M |
| 2 |
Microsoft
MSFT
|
+$163M |
| 3 |
Linde
LIN
|
+$133M |
| 4 |
Amazon
AMZN
|
+$94.7M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$82.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.34% |
| 2 | Financials | 14.16% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.06% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Greenlight Captial
GLRE
$510M
| $368K | ﹤0.01% |
40,278
-6,122
| -13% | -$56.1K |
|
2702
Avita Medical
RCEL
$228M
| $368K | ﹤0.01% |
+17,911
| New | +$353K |
|
2703
Atomera
ATOM
$213M
| $367K | ﹤0.01% |
17,132
+3,029
| +21% | +$62.2K |
|
2704
Olema Pharmaceuticals
OLMA
$1.05B
| $367K | ﹤0.01% |
13,134
+2,168
| +20% | +$61.7K |
|
2705
Stereotaxis
STXS
$140M
| $367K | ﹤0.01% |
38,110
+3,551
| +10% | +$28K |
|
2706
Spyre Therapeutics
SYRE
$9.19B
| $367K | ﹤0.01% |
2,107
+254
| +14% | +$46.2K |
|
|
APLT
2707
DELISTED
Applied Therapeutics
APLT
| $366K | ﹤0.01% |
17,611
+1,869
| +12% | +$35.4K |
|
2708
Evolus
EOLS
$481M
| $366K | ﹤0.01% |
28,951
+4,572
| +19% | +$50.3K |
|
2709
Limoneira
LMNR
$254M
| $366K | ﹤0.01% |
20,837
-2,369
| -10% | -$43.4K |
|
2710
Rush Enterprises Class B
RUSHB
$6.08B
| $365K | ﹤0.01% |
14,337
-2,204
| -13% | -$63.3K |
|
2711
UroGen Pharma
URGN
$2.3B
| $365K | ﹤0.01% |
23,903
-2,675
| -10% | -$48.4K |
|
2712
AgEagle Aerial Systems
UAVS
$53.5M
| $363K | ﹤0.01% |
+69
| New | +$378K |
|
2713
Citius Pharmaceuticals
CTXR
$18.7M
| $362K | ﹤0.01% |
+4,161
| New | +$250K |
|
2714
Cue Biopharma
CUE
$114M
| $361K | ﹤0.01% |
1,034
-69
| -6% | -$26.7K |
|
2715
Spruce Power Holding Corp
SPRU
$41.7M
| $361K | ﹤0.01% |
+5,415
| New | +$319K |
|
2716
Aveanna Healthcare
AVAH
$2.05B
| $360K | ﹤0.01% |
+29,109
| New | +$345K |
|
|
KNTE
2717
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $360K | ﹤0.01% |
15,455
+3,758
| +32% | +$95.6K |
|
|
LTRPA
2718
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
| $360K | ﹤0.01% |
88,473
-34,431
| -28% | -$167K |
|
2719
Puma Biotechnology
PBYI
$430M
| $358K | ﹤0.01% |
39,041
-2,448
| -6% | -$24.8K |
|
2720
Tonix Pharmaceuticals
TNXP
$187M
| $358K | ﹤0.01% |
+1
| New | +$735K |
|
2721
Commercial Vehicle Group
CVGI
$150M
| $356K | ﹤0.01% |
+33,464
| New | +$370K |
|
2722
iShares Russell 2000 Value ETF
IWN
$14.6B
| $355K | ﹤0.01% |
+2,140
| New | +$353K |
|
|
NAPA
2723
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $355K | ﹤0.01% |
+16,103
| New | +$313K |
|
|
YELL
2724
DELISTED
Yellow Corporation Common Stock
YELL
| $354K | ﹤0.01% |
+54,441
| New | +$405K |
|
|
SYRS
2725
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $353K | ﹤0.01% |
6,472
+1,802
| +39% | +$107K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, RhumbLine Advisers held 3,238 positions worth $76.2B, up 3.5% from $73.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers withdrew a net $2.97B in Q2 2021, closing 243 positions and reducing 2,065 holdings. Its most notable exit was Varian Medical Systems, Inc., an estimated $32.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
Against the trend, RhumbLine Advisers opened a new position in DraftKings worth $14.2M.
- RhumbLine Advisers's largest Q2 2021 buy was DraftKings: 271,227 shares worth $14.2M.
- RhumbLine Advisers added most to iShares Core S&P 500 ETF in Q2 2021, an estimated $77.3M increase.
- RhumbLine Advisers's biggest Q2 2021 reduction was Apple, cutting an estimated $206M.
- RhumbLine Advisers fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $32.1M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $76.2B portfolio in Q2 2021.
- RhumbLine Advisers opened 235 new positions and closed 243 in Q2 2021.
- RhumbLine Advisers's portfolio value rose 3.5% quarter-over-quarter to $76.2B.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.